Screener / SEC EDGAR /CIK 0001743881 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

BridgeBio Pharma, Inc. BBIO

Compare with peers Embed
SEC comment letters, last 20 years

1 review of BBIO's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Mar 14, 2019
Questions asked 36 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 36 numbered comments
  3. 3. Company replies 6 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-1

2019-03-14 to 2019-06-25 · 36 questions · 5 letters from the SEC, 6 from the company
No closing letter
Results discussion (MD&A)Legal and contingenciesCritical estimates
Prospectus Summary · Overview, page 1
SEC asked (1)
We note your disclosure that several of your programs target potential “blockbuster” opportunities. Please tell us the definition you use to define a blockbuster opportunity, and place this selected disclosure in appropriate context by specifying the programs and indications you believe present blockbuster opportunities and whether the related programs are in the clinical, preclinical or lead optimization stage.
Rest of the question

For those programs that are lead optimization or preclinical stage, please tell us why you believe it is appropriate to characterize these as blockbuster opportunities given the early stage of development.

BBIO answered
Confidential Treatment Request by BridgeBio Pharma, Inc. This letter is being provided on behalf of BridgeBio Pharma, Inc., a Delaware corporation (the “Company”), with respect to the Company’s Registration Statement on Form S-1 (File No. 333-231759) (as amended, the “Registration Statement”), that was initially filed with the Securities and Exchange Commission (the “Commission”) on May 24, 2019. Reference is also made to Comment No.
Rest of the letter

14 in the letter from the staff of the Division of Corporation Finance (the “Staff”) of the Commission in its letter dated March 14, 2019 addressed to Neil Kumar, Ph.D., the Chief Executive Officer of the Company, with respect to the initial draft of the Registration Statement confidentially submitted on February 14, 2019. To assist the Staff in its evaluation of equity compensation disclosures and certain other matters in the Registration Statement, the Company advises the Staff that, considering information currently available and current market conditions based in part on input received from its underwriters, the Company currently estimates a price range of $[***] to $[***] per share for the initial public offering (“IPO”) of the Company’s Common Stock, $0.001 par value per share (which is referred to in the Registration Statement as the Company’s “common stock”), as further outlined below. As described beginning on page 85 of the Registration Statement, in connection with the IPO, the Company will create BridgeBio Merger Sub LLC as a wholly-owned subsidiary of the Company, and BridgeBio Merger Sub LLC will merge with and into BridgeBio Pharma LLC (the “LLC”), with the LLC as the surviving entity in the merger as a wholly-owned subsidiary of the Company (the “Reorganization”). As part of the Reorganization, the holders of existing units in the LLC will exchange those units for shares of common stock of the Company, after which those holders will have received 100% of the outstanding capital stock of the Company as of immediately prior to the completion of the IPO. The capital stock of the Company will be allocated to the holders of existing Series D preferred units, Series C preferred units, Series B preferred units, Series A preferred units, founder units, common units and management incentive units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC (the “LLC Agreement”), based upon the liquidation value of the LLC assuming it was liquidated immediately prior to the completion of the IPO. In connection with the Reorganization, the holders of the outstanding incentive equity of the LLC, which is currently comprised of management incentive units and common units of the LLC, will be entitled to exchange such units for shares of the common stock and restricted common stock of the Company in an amount equal to (a) the dollar amount that would be distributable to such holders in respect of such units at the liquidation value of the LLC in accordance with the terms of the LLC Agreement, divided by (b) the price per share of the common stock to be sold by the Company in the IPO. The Company estimates a valuation range of $[***] to $[***] for the LLC as of immediately prior to the IPO and intends to issue an aggregate of 100.0 million shares of common stock, which will represent all of the Company’s issued and outstanding common stock prior to the planned IPO, to the holders of existing units in the LLC in connection with the Reorganization. Accordingly, the Company estimates an IPO price range of $[***] to $[***] per share of common stock. For clarity, the Company advises the Staff that, given the volatility of the public trading market and the uncertainty of the timing of the offering, the Company and the underwriters have not yet agreed to a final price range for the offering. Accordingly, the actual price range may differ in the actual preliminary prospectus for the offering. We confirm on behalf of the Company that, prior to circulating copies of the preliminary prospectus in connection with the offering, the Company will file a pre-effective amendment to the Registration Statement that will include the actual price range that complies with the Staff’s interpretation regarding the parameters of a bona fide price range. BridgeBio Pharma, Inc. respectfully requests that the bracketed information contained in this letter be treated as confidential information and that the Commission provide timely notice to Brian Stephenson, Chief Financial Officer, BridgeBio Pharma, Inc., 421 Kipling Street, Palo Alto, CA 94301, before it permits any disclosure of the bracketed information in this letter. The LLC has outstanding 48,690,602 management incentive units granted before November 2018 (referred to as “Prior Units”) and 24,111,064 management units granted on February 12, 2019 (referred to as “February 2019 Units”). The difference in fair value between the Prior Units and February 2019 Units is due to the increased participation threshold for the February 2019 Units relative to that of the Prior Units. Based on the pre-IPO implied equity valuation range of $[***] to $[***] described above, each management incentive unit in the LLC will be exchanged for a number of shares of common stock of the Company determined by dividing (a) the dollar amount of the fair value distributable in respect of such management incentive unit in the Reorganization under the terms of the LLC Agreement, as shown in the table below, by (b) the price per share of the common stock to be issued in the IPO based on the implied valuation of the LLC as of immediately prior to the Reorganization and assuming a total of 100.0 million shares of common stock outstanding in the Company immediately prior to the IPO. As noted above, the Company anticipates an IPO price range of $[13.00] to $[18.00] per share of common stock based on the implied equity valuation range set forth above and assuming the issuance of a total of 100.0 million shares of common stock in the Reorganization immediately prior to the IPO. Determining the Fair Value of Equity-Based Compensation Prior to the IPO As stated in the Registration Statement, equity-based compensation is measured on the grant date for the LLC’s management incentive units and common units based on the fair value of the awards using either an option pricing model (“OPM”) or Probability-Weighted Expected Return Method (“PWERM”). Equity-based compensation is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The management incentive units and common units awarded generally only have a service condition and vest over a period of up to five years. The Company has elected to recognize the actual forfeitures by reducing the employee equity-based compensation expense in the same period as the forfeitures occur. The Registration Statement describes the LLC’s use of valuation models and describes the significant assumptions used during the years ended December 31, 2017 and 2018 and the three months ended March 31, 2019. As described on page 107 in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of the prospectus included within the Registration Statement, which includes an explanation of the LLC’s approach to accounting for equity-based compensation, the LLC has historically determined the fair value of its management incentive units and common units using methodologies, approaches and assumptions consistent with the following accounting guidance: American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “AICPA Practice Guide”); Accounting Standards Codification (“ASC”) 718, Compensation—Stock Compensation Various Commission Staff Speeches and guidance. In addition, the LLC’s Board of Managers also considered numerous objective and subjective factors, as disclosed in the Company’s most recent filing of the Registration Statement on June 11, 2019, along with input from management and third-party valuations, to determine the fair value of the LLC’s management incentive units. The section captioned “Equity-based compensation” on page 107 in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of the Registration Statement includes an explanation of the LLC’s approach to accounting for equity-based compensation, including the methodology and factors used by the LLC to determine the fair value of the LLC’s management incentive units. To facilitate the Staff’s review, we have included the table below, which is a complete list of all grants of management incentive units made from March 31, 2018 through the date of this letter. There have been no grants of common units from March 31, 2018 through the date of this letter. The Company determined that the fair value of the LLC’s Prior Units increased from $0.60 per unit as of the July 2018 grant date to $1.63 per unit as of March 31, 2019. The holders of Prior Units would receive between $[***] to $[***] per unit when the Reorganization occurs No MIU grants occurred after February 12, 2019. based on the pre-IPO implied equity valuation range described above. For the February 2019 Units, the Company utilized the March 31, 2019 valuation fair value of $0.78 per unit. The February 2019 Units would receive between $[***] to $[***] per unit when the Reorganization occurs based on the pre-IPO implied equity valuation range described above. The following discussion describes the reasons for the increases in the fair value of the LLC’s management incentive units over the applicable periods. The assumptions used in the valuation model to determine the estimated fair value of the LLC’s management incentive units as of the grant date of each award are based on numerous objective and subjective factors, combined with management judgment, including the following: progress of the LLC’s research and development efforts; the impact of significant corporate events or milestones, including the negotiation and closings of the LLC’s Series D preferred unit financing (the “Series D Preferred Unit Financing”); the LLC’s overall prospects for future earnings; the LLC’s actual operating results and financial condition, including the LLC’s level of available capital resources; rights, preferences and privileges of the LLC’s preferred units, founder units and common units relative to those of the management incentive units; equity market conditions affecting comparable public companies; the likelihood and potential timing of achieving a liquidity event for the shares of the Company’s common stock, such as an initial public offering given prevailing market and biotechnology sector conditions; and the lack of marketability of the LLC’s management incentive units. Management Incentive Unit Valuation Methodologies The AICPA Practice Guide identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the AICPA Practice Guide, the Company considered the following methods: Option Pricing Method. Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred units, founder units, common units and management incentive units are inferred by analyzing these options. Probability-Weighted Expected Return Method. The PWERM is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment. At each grant date, the LLC’s Board of Managers reviewed any recent events affecting the LLC since the date of the last third-party valuation and the potential impact of such events on the estimated fair value per unit of the LLC’s management incentive units. For grants of equity awards made on dates for which there was no valuation available from an independent valuation specialist, the LLC’s Board of Managers determined the fair value of the LLC’s management incentive units on the date of grant based upon an interpolation of the immediately preceding valuation and immediately following valuation and other pertinent information available to it at the time of grant. The fair value of management incentive units is based primarily on the valuation reports performed by a third-party provider, which is reviewed and approved by the LLC’s Board of Managers as of that date. The application of either the OPM or PWERM valuation methods, the incorporation of multiple liquidity scenarios and a discount for lack of marketability (“DLOM”) in each scenario, and the application of our estimates of the probability of an IPO at each applicable valuation date resulted in the following determinations of the estimated fair value of the Prior Units and the February 2019 Units at each date: June 30, 2018 Valuation: The LLC received an independent third-party valuation of its management incentive units as of June 30, 2018 that indicated that the fair value of the LLC’s equity was $[***] million and the fair value of each management incentive unit on that date was $0.60 per unit (the “June 30 Valuation Report”). The independent valuation specialist valued the equity of the LLC using the cost approach, valuing each underlying investment of the LLC separately. The equity value of the LLC was allocated to the management incentive units using the OPM method. A DLOM of 17.5% was applied to the unadjusted fair value of the management incentive units due to the LLC being privately held. November 20, 2018 Valuation: The LLC received an independent third-party valuation of its management incentive units as of November 20, 2018 that indicated that the fair value of the LLC’s equity was $[***] million and the fair value of each management incentive unit on that date was $0.98 per unit (the “November 20 Valuation Report”). This valuation relied primarily on the PWERM method, weighting the values of the equity under both an IPO scenario and a remain private scenario. In the IPO scenario, the equity value was determined by making an assumption of the LLC’s pre-money valuation at the time of a potential IPO. In the remain private scenario, the LLC’s equity value was backsolved in order to reconcile to the valuation implied by the price at which the Series D preferred units were issued in the Series D Preferred Unit Financing. A 30.0% DLOM was applied to the unadjusted fair value of each management incentive unit calculated in the remain private scenario due to the LLC being privately held and an 11.0% DLOM was applied to the unadjusted fair value of each management incentive unit calculated in the IPO scenario. The increase in the value of the LLC and the unit valuation between June 30, 2018 and November 20, 2018 was largely driven by key scientific advancements including: positive data from the BBP-265 Phase 2 clinical trial in November 2018 and FDA acceptance of an IND for BBP-589 in October 2018. December 31, 2018 Valuation: The LLC received an independent third-party valuation of its management incentive units as of December 31, 2018 that indicated that the fair value of the LLC’s equity was $[***] million and the fair value of each management incentive unit on that date was $1.30 per management incentive unit (the “December 31 Valuation Report”). This valuation relied primarily on the PWERM method, weighting the values of the equity under both an IPO scenario and a remain private scenario. The probability of an IPO was increased from the November 20 Valuation Report as a result of the following events between November 20, 2018 and December 31, 2018: (i) the LLC had terminated preparations for a potential IPO for one of its consolidated entities, (ii) the LLC had identified its lead underwriting banks for a potential IPO of the LLC or a successor entity thereto in accordance with the LLC Agreement, (iii) the LLC had held a preliminary planning meeting for the IPO, (iv) substantial progress had been made in the audit of the LLC’s financial statements, (v) executive management began to allocate a larger portion of their time to investigating a potential IPO, (vi) the LLC’s internal finance team had begun to grow in preparation for public company reporting requirements, and (vii) public market conditions had improved. In the IPO scenario, the equity value was determined by making an assumption of the LLC’s pre-money valuation at the time of a potential IPO, and this value assumption was the same as what was incorporated into the November 20 Valuation Report. In the remain private scenario, the LLC’s equity value was set equal to the same remain private equity value that was determined in the November 20 Valuation Report, which at the time was based on a reconciliation of the price at which the Series D preferred units were issued in the Series D Preferred Unit Financing. A 30.0% DLOM was applied to the unadjusted fair value of each management incentive unit calculated in the remain private scenario due to the LLC being privately held and an 10.0% DLOM was applied to the unadjusted fair value of each management incentive unit calculated in the IPO scenario. The completion of the LLC’s Series D Preferred Unit Financing in November and December 2018 for an aggregate purchase price of $299.2 million also generated cash sufficient to fund the Company’s operations for at least the next 12 months and significantly strengthened the Company’s balance sheet. In addition, the increase in the value of the LLC and the unit valuation between November 20, 2018 and December 31, 2018 was largely driven by key scientific and corporate advancements including: (a) PellePharm, Inc.’s execution of an option agreement with LEO Pharma A/S, pursuant to which, among other things, PellePharm, Inc. received certain exclusivity payments from LEO Pharma A/S in November 2018, (b) the receipt of positive feedback from FDA meetings held by Eidos Therapeutics, Inc. with respect to the design of the Phase 3 clinical trial for BBP-265 in December 2018 and (c) receipt of positive data from a pre-clinical study of BBP-631 in non-human primates demonstrating three-month persistence in December 2018. March 31, 2019 Valuations: The LLC received an independent third-party valuation of its management incentive units as of March 31, 2019. The report indicated that the fair value of LLC’s equity was $[***] million, and the fair value of the Prior Units was $1.63 per unit and the fair value of the February 2019 Units was $0.78 per unit. This valuation relied primarily on the PWERM method, weighting the values of the equity under both an IPO scenario and a remain private scenario. The probability of an IPO was increased from the December 31 Valuation Report as (i) the LLC had held an organizational meeting with investment banks, (ii) the LLC had confidentially submitted a Draft Registration Statement with the SEC, including audited financial statements for the year ended December 31, 2017, (iii) significant progress had been made in the audit of the LLC’s 2018 financial statements, and (iv) the LLC’s finance team had grown significantly in preparation for potential reporting requirements as a public company. In the IPO scenario, the equity value was determined by making an assumption of the LLC’s pre-money valuation at the time of a potential IPO. In the remain private scenario, the independent valuation specialist valued the equity of the LLC using the cost approach, valuing each underlying investment of the LLC separately. The difference in value between the Prior Units and the February 2019 Units was driven by the increased participation threshold of the February 2019 Units relative to that of the Prior Units, and application of different DLOM adjustments to the fair values calculated for each of the Prior Units and the February 2019 Units, also due to the difference in participation thresholds. A 22.5% DLOM was applied to the unadjusted fair value of each Prior Unit calculated in the remain private scenario due to the LLC being privately held and a 7.5% DLOM was applied to the unadjusted fair value of each Prior Unit calculated in the IPO scenario. A 27.5% DLOM was applied to the unadjusted fair value of each February 2019 Unit calculated in the remain private scenario due to the LLC being privately held and a 10.0% DLOM was applied to the unadjusted fair value of each February 2019 Unit calculated in the IPO scenario. The increase in the value of the LLC and the unit valuation between December 31, 2018 and March 31, 2019 was largely driven by key clinical and scientific advancements at the LLC’s subsidiaries, including (a) Eidos Therapeutics, Inc.’s initiation of its Phase 3 clinical trial of BBP-265 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) in February 2019, (b) Phoenix Tissue Repair, Inc.’s dosing of the first patient in the Phase 1/2 trial of BBP-589 in February 2019, (c) Navire Pharma, Inc.’s selection of a development candidate for the BBP-398 program in February 2019 and (d) Adrenas Therapeutics, Inc.’s receipt of data from ongoing preclinical studies of BBP-631 in non-human primate models demonstrating six-month persistence in March 2019. Comparison of Estimated Offering Price Range and Recent Fair Value Determination As of March 31, 2019, the estimated fair value per management incentive unit is $1.63 per Prior Unit and $0.78 per February 2019 Unit based on an estimated equity valuation of $[***]. As discussed above, the holders of Prior Units would receive between $[***] to $[***] per unit and the holders of February 2019 Units would receive between $[***] to $[***] per unit when the Reorganization occurs based on the pre-IPO implied equity valuation range set forth in this letter. The estimated pre-IPO equity valuation range has been determined by the Company in consultation with the underwriters in the offering and with reference to several quantitative and qualitative factors, each of which contributed to the difference between the estimated fair value per management incentive unit as of March 31, 2019 and the LLC’s most recent estimated valuation as of March 31, 2019. Specifically, the Company believes that the difference between the fair value of the LLC’s management incentive units determined on March 31, 2019 and the implied value of the LLC’s management incentive units at the time of the planned IPO is primarily the result of the following factors and events: In April 2019, BBP-589 received Fast Track designation from the FDA, and enrollment was opened in the second cohort of its Phase 1/2 clinical trial. The anticipated price range for this offering assumes that the IPO has occurred and that a public market for the Company’s common stock has been created, and, therefore, excludes any DLOM of the Company’s common stock, which was appropriately taken into account in the LLC’s determination of the fair value of its common units and management incentive units for all valuation dates discussed above. Stated differently, the anticipated offering price range effectively assigns a probability of 100% to an IPO outcome. The anticipated price range for this offering is based only upon a scenario in which the Company completes an IPO and is not probability weighted, in contrast to the LLC’s prior valuations of common units and management incentive units, which had to consider multiple potential outcomes, some of which would have resulted in a lower value of the LLC’s common units and management incentive units than in an IPO. The holders of the LLC’s redeemable convertible preferred units currently enjoy substantial economic rights and preferences over the holders of its founder units, common units, and management incentive units. In particular, the holders of redeemable convertible preferred units are entitled to receive liquidation payments prior to holders of all other unit classes in the event of any liquidation, dissolution or wind up of the LLC. In addition, holders of the LLC’s redeemable convertible preferred units are entitled to receive cumulative returns prior to any dividends declared or paid on any units of the LLC’s other unit classes and have voting rights with respect to certain specified actions by the LLC. In connection with the Reorganization, all of the LLC’s redeemable convertible preferred units will be exchanged for shares of the Company’s common stock in the Reorganization, and therefore, the right of the preferred unit holders to accrue additional cumulative returns and their special voting rights will terminate upon the Reorganization. The anticipated elimination of these preferences and rights upon an IPO results in an increased common unit and management incentive unit valuation for the anticipated price range. The proceeds of a successful IPO would substantially strengthen the Company’s balance sheet by increasing its cash resources. In addition, the completion of this offering would provide the Company with readier access to the public debt and equity markets. These projected improvements in the Company’s financial position influenced the increased common stock valuation indicated by the midpoint of the anticipated price range. The price that investors may be willing to pay in this offering may take into account factors that have not been expressly considered in the LLC’s prior valuations as a private company, and are not objectively determinable and that valuation models are not able to quantify. The LLC has historically determined the fair value of its management incentive units and common units consistent with the guidance set forth in the AICPA Practice Guide, including, specifically, its use of the hybrid method using a probability weighting of the OPM and PWERM scenarios, which is an accepted valuation method under the AICPA Practice Guide. The Company believes that the probability weighting of each potential liquidity event used in the LLC’s fair value analysis was reasonable at the time, in light of the LLC’s stage of development, including the status of its research and development efforts and financial position, external market conditions affecting the biotechnology industry, the volatility in the capital markets, especially with respect to initial public offerings, and the relative likelihood of achieving a liquidity event such as an initial public offering or sale of the Company in light of prevailing market conditions. The Company believes the deemed fair value of the management incentive units and common units used as the basis for determining equity-based compensation expense for financial reporting purposes is reasonable and appropriate based on the above referenced factors. Because of the financially sensitive nature of the estimated price range, the Company requests confidential treatment under 17 C.F.R. § 200.83 of the contents of this letter and has submitted a separate request for confidential treatment in accordance therewith to the Commission’s Office of Freedom and Information Privacy Act Operations. Kindly acknowledge receipt of this letter by stamping the enclosed copy of this letter and returning it in the envelope provided. If you should have any questions concerning the enclosed matters, please contact the undersigned at (415)

One letter for all the questions, without numbered answers. Read the reply
Our Platform, page 2
SEC asked (2)
We note your disclosure that you “rapidly” advance your product candidates to objective critical decision points. Please revise your disclosure and similar statements throughout your registration statement, e.g., on page 31, to remove any implication that you will be successful in commercializing your product candidates in a rapid or accelerated manner as these statements are speculative for you to make.
Rest of the question

Similarly, please remove statements that imply you will be successful in mitigating risk associated with drug development, such as your statement on page 114 that you "avoid taking on the risk associated with scientific uncertainties often seen with novel modalities" and your statements throughout that you focus on programs that you believe to be "lower development risk."

BBIO answered

See the reply above.

Our Pipeline, page 3
SEC asked (3)
We note your reference to “promising” oncology programs and other references to your product candidates as potential "first-in-class" or “best-in-class” therapies. These terms suggest that the product candidates are effective and likely to be approved. Please delete these references throughout your registration statement.
Rest of the question

If your use of these terms was intended to convey your belief that the products are based on a novel technology or approach and/or is further along in the development process, you may discuss how your technology differs from technology used by competitors and, if applicable, that you are not aware of competing products that are further along in the development process. Statements such as these should be accompanied by cautionary language that the statements are not intended to give any indication that the product candidates have been proven effective or that they will receive regulatory approval.

BBIO answered

See the reply above.

Our Pipeline, page 3
SEC asked (4)
Please refine the description of your pipeline by categories so that it presents a balanced view of the status of such programs. For example, please state that three out of four of your oncology product candidates are in the lead optimization phase.
BBIO answered

See the reply above.

Our Pipeline, page 3
SEC asked (5)
Please tell us why you believe that BBP-265, BBP-831, BBP-631 and BBP-454 have the greatest potential to drive near-term value. We note other similarly situated programs in your pipeline in terms of stage of development and patient population. In addition, BBP631 and BBP-454 are in very early stages of development, so it is unclear how they would provide value in the near-term.
Rest of the question

Please also clarify if you intend to prioritize the funding of these programs over your other programs, as is suggested by disclosure on page 15 and elsewhere in your filing.

BBIO answered

See the reply above.

Our Pipeline, page 3
SEC asked (6)
We note your disclosure on pages 5 and 133 concerning the development plan for BBP831/Infigratinib. As you have not yet commenced any Phase 3 trials or submitted a new drug application (NDA) for this product candidate for any indication, please shorten the arrow in your pipeline development chart so that it reflects the current stage of development.
Rest of the question

Please also revise the "Current Status" column in the chart on page 116 accordingly. In addition, please clarify that your preparation for an NDA submission is with respect to BBP-831 only for use as a second-line therapy.

BBIO answered

See the reply above.

Our Pipeline, page 3
SEC asked (7)
Please tell us what is meant that three of your product candidates are "Registrational." To the extent this indicates that they have completed the trial prior to your submission of an NDA, we note your disclosure on page 133 that you expect to enroll approximately 20 additional subjects in the ongoing CCA Phase 2 clinical trial and your Phase 2 clinical trial for BBP-870 is also ongoing.
Rest of the question

Please tell us the significance of indicating that these trials are registrational as opposed to indicating their current status or that they have completed a particular trial phase.

BBIO answered

See the reply above.

Our Pipeline, page 3
SEC asked (8)
Your pipeline table appears to include every in-house development program. Please revise the table to include only those programs that are material to the company. If you believe that every program listed is material, please provide us with an analysis explaining your belief. In particular, to the extent your programs in the lead optimization stage are material to the company, please discuss this in your analysis.
BBIO answered

See the reply above.

Who Should Invest, page 4
SEC asked (9)
Please delete the disclosure in this section as it presents itself as a disclaimer that only particular investors should invest in the company.
BBIO answered

See the reply above.

Risks Associated with Our Business , page 7
SEC asked (10)
Please expand your disclosure in the fourth bullet point to highlight the risks associated with developing gene therapy candidates, as discussed on pages 28 to 31. Please also expand the disclosure in the seventh bullet point to disclose competition with respect to your key value drivers, as discussed on page 60, and in the penultimate bullet point to disclose pending patent litigation, as discussed on page 45.
Rest of the question

Additionally, please add a bullet point to highlight the risk that as a result of concentration of share ownership, existing shareholders will be able to exert significant influence over matters subject to shareholder approval, as discussed on page 73, and a bullet point discussing the risk that you may expend your limited resources to pursue a particular product candidate and fail to capitalize on more profitable development opportunities.

BBIO answered

See the reply above.

Implications of Being An Emerging Growth Company, page 9
SEC asked (11)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
BBIO answered

See the reply above.

Use of Proceeds, page 82
SEC asked (12)
Please expand your disclosure to specify the intended use of proceeds, including the amount you intend to allocate to each product candidate individually and how far the net proceeds are expected to allow you to continue in the development for each of your product candidates. Refer to Item 504 of Regulation S-K.
BBIO answered

See the reply above.

Reorganization, page 84
SEC asked (13)
We note that, in connection with your corporate reorganization, you will issue shares of BridgeBio Pharma, Inc. to holders of existing units in BridgeBio Pharma LLC in exchange for the LLC units. Please tell us whether you are relying on an exemption from registration for the issuance to unitholders, including the facts supporting such exemption.
BBIO answered

See the reply above.

Critical Accounting Policies and Estimates · Equity-Based Compensation, page 101
SEC asked (14)
Once you have an estimated offering price or range, please explain to us how you determined the fair value of the units underlying your equity issuances and the reasons for any differences between the recent valuations of your units leading up to the IPO and the estimated offering price.
Rest of the question

This information will help facilitate our review of your accounting for equity issuances including stock compensation and beneficial conversion features.

BBIO answered

See the reply above.

BBP-265/AG10 (Eidos): TTR Amyloidosis · Our Product Concept, page 118
SEC asked (15)
We note your reference to cross-study comparisons of clinical data here and presentation of prospective and retrospective study data on pages 117, 118 and 120, including the chart on page 120, and your discussion of cross-trial comparisons with respect to additional product candidates on pages 128, 129, 135, 138, 150 and 151.
Rest of the question

Please remove any comparisons with third party treatments, including your perceived advantage over existing therapies and therapies in development, such as those discussed on page 125, as the data and your conclusions are not based on head-to-head studies.

BBIO answered

See the reply above.

BBP-831/Infigratinib (QED): FGFR-Driven Cancers · Clinical Data, page 129
SEC asked (16)
We note statements throughout stating that Infigratinib has shown "meaningful clinical activity" and "significant clinical activity." Please tell us what you mean by meaningful and significant, including the measurements you are using to make such determinations.
BBIO answered

See the reply above.

BBP-831/Infigratinib (QED): FGFR-Driven Cancers · Clinical Data, page 129
SEC asked (17)
Please expand your disclosure to include the objective data points for each of ORR, PFS, BOR, DCR and OS, and how the interim analysis results compare to the established endpoints. Please provide similar disclosure for the trial discussed on page 131 and in your discussion of results on page 133 so that investors can understand the significance of the results.
BBIO answered

See the reply above.

BBP-831/Infigratinib (QED): FGFR-Driven Cancers · Clinical Data, page 129
SEC asked (18)
Please explain the significance of the waterfall charts on pages 130-131.
BBIO answered

See the reply above.

BBP-831/Infigratinib (QED): FGFR-Driven Cancers · Clinical Data, page 129
SEC asked (19)
We note your statement on page 133 that your plan to discuss the marketing authorization pathway for the companion diagnostic you are developing. On page 37 you note that the FDA will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of diagnostics, which you expect will require separate regulatory clearance or approval.
Rest of the question

Please revise your disclosure to explain how approval of your diagnostic tool for BP-831 impacts the timing of approval and/or commercialization of BBP-831. Please also disclose the impact to approval and or/marketing of BBP-831 if the diagnostic tool is not approved.

BBIO answered

See the reply above.

Safety Data, page 131
SEC asked (20)
Please disclose all serious adverse events experienced by patients exposed to infigratinib, whether or not treatment related, including the incidence of each serious adverse event.
BBIO answered

See the reply above.

BBP-870 (Origin): MoCD Type A, page 144
SEC asked (21)
Please disclose all serious adverse events that occurred in the Phase 2 and Phase 2/3 clinical trials, whether or not related to BBP-870. BBP-009/Patidegib (PellePharm): Gorlin Syndrome and High Frequency Basal Cell Carcinoma,
BBIO answered

See the reply above.

BBP-870 (Origin): MoCD Type A, page 144
SEC asked (22)
Please disclose the primary and secondary endpoints for each of the Phase 2 clinical trials in terms of their objective data points and how the results of the studies compared to the endpoints. Please also disclose data supporting your statement that the Phase 2 trial showed statistically significant levels of clearance of BCCs after three months.
Rest of the question

Please ensure that you present a complete picture of all results so that investors can understand the significance of the results that you cite. Please also disclose all serious adverse events, whether or not treatment-related.

BBIO answered

See the reply above.

Intellectual Property, page 173
SEC asked (23)
Please expand your disclosure to indicate the relevant jurisdiction for each of your foreign patents. Refer to Item 101(c)(1)(iv) of Regulation S-K.
BBIO answered

See the reply above.

Our Material Agreements · BBP-831 License Agreement with Novartis International Pharmaceutical Ltd. , page 177
SEC asked (24)
Please expand your disclosure to quantify the value of the shares of Series A preferred stock to be issued to Novartis under the license agreement. Please provide similar disclosure with respect to the common shares issued to Lotus under the asset purchase agreement for BPP-589 referenced on page 177 and with respect to the common shares issued under the collaboration and license agreement with the Board of Regents
Rest of the question

of the University of Texas System, as referenced on page 180.

BBIO answered

See the reply above.

BBP-009 (Patidegib): Option Agreement with LEO Pharma A/S, page 178
SEC asked (25)
Please disclose the certain events that would prevent LEO Pharma from exercising its option to acquire PellePharm.
BBIO answered

See the reply above.

General
SEC asked (26)
Please ensure that all graphics are legible, including your pipeline development charts, and provide us proofs of all graphics, visual, or photographic information you will provide in the printed prospectus prior to its use, for example in a preliminary prospectus. Please note that we may have comments regarding this material.
BBIO answered

See the reply above.

SEC letter of Apr 30, 2019 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary · Our Platform, page 2
SEC asked (1)
We note your revisions in response to our prior comment 2. Please further revise statements in your prospectus that imply you will be successful in mitigating risk associated with drug development. We note, for example, your statement on page 2 that you pursue programs with validated treatment modalities, which you believe allows you to avoid the increased risk associated with less tested approaches.
Rest of the question

Please revise your disclosure throughout to remove the suggestion that your drug candidates are part of validated treatment modalities and that you can lessen the risks of drug development.

BBIO answered

No reply letter found.

Our Investment Thesis, page 4
SEC asked (2)
We note your response to comment 9 and continue to view these statements as inappropriate. As you have not yet successfully commercialized any product candidates or translated a "pool" of "innovation" into "life-changing medicines," this discussion does not appear appropriately tailored to your business.
Rest of the question

In addition, the fact that your business is subject to short-term variance and you manage your business by focusing on long-term decisions does not appear to be unique. Please revise this disclosure to present balanced, factual information related to your business plan, or remove this disclosure. Please also tell us why you believe the company's business model represents a "new type of company" and provide support for your statement on page 1 that your focus on early-stage development is "often-overlooked" as well as your statement on page 3 that other companies have "excess overhead" which you have been able to eliminate. Our Pipeline, page 4

BBIO answered

No reply letter found.

Our Investment Thesis, page 4
SEC asked (3)
We note your response to comment 7 and the footnote disclosure to your pipeline chart. We do not agree that your use of the term "registrational" is appropriate due to the uncertainty. Please remove such references to "registrational" trials here and throughout your registration statement.
BBIO answered

No reply letter found.

Management's Discussion and Analysis of Financial Condition and Results of Operations · Basis of Presentation and Consolidation, page 96
SEC asked (4)
Please clarify how the 52.1% ownership interest in PellePharm, Inc. at December 31, 2018 was calculated. In this regard, we note that at the date of deconsolidation in November 2018 you owned an 8% common stock interest and a 61.9% preferred stock interest in PellePharm, Inc.
BBIO answered

No reply letter found.

BBP-831/Infigratinib (QED): FGFR-Driven Cancers · Clinical Development Plans , page 139
SEC asked (5)
We note your response to comment 19, which we reissue in part. Please expand your disclosure to disclose the impact to approval and/or marketing of infigratinib in the event your companion diagnostic is not approved.
BBIO answered

No reply letter found.

BBP-009/Patidegib (PellePharm): Gorlin Syndrome and High Frequency Basal Cell Carcinoma · Clinical Data, page 157
SEC asked (6)
We note your response to comment 22. Please expand your disclosure to define the term "complete clinical response" in this context.
BBIO answered

No reply letter found.

Notes to Combined and Consolidated Financial Statements
SEC asked (7)
Noncontrolling Interests , page F-32 7. Please provide your analysis supporting the amounts recorded in the rebalancing adjustment due to change in ownership during 2018. Please tell us the basis for the adjustments and cite the applicable GAAP guidance.
BBIO answered

No reply letter found.

Prospectus Summary · Our Platform, page 2
SEC asked
We note your response to comment 1, which we reissue. You continue to state that you only pursue programs with treatment modalities that have been “validated” in other approved products, which implies that you are able to successfully mitigate development risk. Please remove this disclosure here and on pages 117 and 121.
BBIO answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure accordingly on pages 2, 118 and 122 of the Registration Statement.

If you require additional information, please telephone the undersigned at (415) 733-6071.
Read in the reply
Prospectus Summary · Our Pipeline, page 4
SEC asked
Please add disclosure to your pipeline table to indicate that you have granted a third-party a currently-exercisable option to acquire PellePharm, including the product candidate BBP-009, and if the option is exercised you will no longer have any rights to BBP-009.
BBIO answered
The Company respectfully acknowledges the Staff’s comment and has revised the disclosure accordingly on pages 4, 121 and 126 of the Amended Registration Statement.

In addition, the Company respectfully advises the Staff that in response to the Staff’s Comment No. 12 in the letter dated March 14, 2019 from the Staff to the Company regarding initial confidential submission of the Company’s Draft Registration Statement on February 14, 2019, the Company has provided additional disclosure specifying the intended use of proceeds from the offering, including the amounts that the Company plans to
Rest of the answer

allocate to specified programs and how far such proceeds are expected to allow the Company to continue in development for each such program.

If you require additional information, please telephone the undersigned at (415) 733-6071.

Read in the reply
Exhibits
SEC asked
We note your disclosure on page 250 of your registration statement under the heading "Description of Capital Stock" stating that the forum selection provision in your amended and restated by-laws does not apply to any actions arising under the Securities Act or Exchange Act.
Rest of the question

Please ensure that the exclusive forum provision in your by-laws states this clearly, or tell us how you will inform investors in future filings that the provision does not apply to any actions arising under the Securities Act or Exchange Act.

BBIO answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that, following the closing of the offering, it intends to file a Form 8-K pursuant to Item 5.03 that

Page will contain a summary of the Company’s amended and restated by-laws (the “By-laws”). Such summary will inform investors that the exclusive forum provision contained in the By-laws does not apply to any actions arising under the Securities Act or Exchange Act.
Rest of the answer

The Company will file both the By-laws and its as filed Amended and Restated Certificate of Incorporation as exhibits to the Form 8-K.

If you require additional information, please telephone the undersigned at (415) 733-6071.

Read in the reply

Also in this review: company letter, Jun 24, 2019, company letter, Jun 24, 2019

Letters without questions

Other letters

UPLOAD and CORRESP
3 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 14 letters filed since 2019-03-15. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BBIO/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.